Chronic urticaria is usually difficult to cure, but can be controlled by regular treatment, reduce or eliminate the skin lesions, the treatment of choice for antihistamines, but for some refractory chronic urticaria, can be considered under the advice of the physician injection of omalizumab for treatment. Injectable omalizumab is a humanized monoclonal antibody of recombinant DNA origin, which can selectively bind to human immunoglobulin E (IgE), thus preventing the binding of IgE to the high-affinity IgE receptor of basophils and mast cells, and it is effective in most refractory chronic urticaria. It should be noted that some patients may experience adverse reactions such as headache, fever, epigastric pain and pain, swelling, erythema and itching at the injection site after injection of this product, so it should be contraindicated for those who have allergic reactions to the active ingredient contained in this product or any other excipients.